

### **REMARKS/ARGUMENTS**

The Examiner has required restriction to one of the following inventions:

Groups 1-1477. Claims 1-5, drawn to nucleic acids, vectors, and host cells, with respect to SEQ ID Nos: 1-1477;

Group 1478. Claim 6, drawn to a process for producing PRO polypeptide, with respect to SEQ ID NOs: 1-1477;

Groups 1479-2956. Claim 7, drawn to an isolated PRO polypeptide, with respect to SEQ ID NOs: 1-1477;

Groups 2957-4434. Claims 8-9, drawn to fusion protein comprising a polypeptide of SEQ ID NOs: 1-1477 fused to a heterologous amino acid sequence;

Groups 4435-5912. Claims 10-11, drawn to an antibody that binds to any one of SEQ ID NOs: 1-1477;

Groups 5913-7390. Claims 12-14, drawn to a composition comprising a polypeptide of any one of SEQ ID NOs: 1-1477;

Groups 7391-8868. Claim 15, drawn to an article of manufacture comprising any one of SEQ ID NOs: 1-1477;

Groups 8869-10346. Claims 16-17, drawn to a method of treating an immune related disorder comprising administering a polypeptide of SEQ ID NOs: 1-1477;

Groups 10347-11824. Claim 18, drawn to a method for determining the presence of a PRO polypeptide of SEQ ID NOs: 1-1477 in a sample;

Groups 11825-13302. Claims 19, 20, and 26, drawn to a method of diagnosing an immune related disease comprising detecting the level of expression of any SEQ ID NOs: 1-1477;

Groups 13303-14780. Claim 21, drawn to a method of identifying a compound that inhibits the activity of a PRO polypeptide of SEQ ID NOs: 1-1477;

Groups 14781-16258. Claims 22-23, drawn to a method of identifying a compound that inhibits the expression of a gene encoding a PRO polypeptide of SEQ ID NOs: 1-1477;

Groups 16259-17736. Claim 24, drawn to a method of identifying a compound that mimics the activity of a PRO polypeptide of SEQ ID NO: 1-1477; and

Groups 17737-19214. Claim 25, drawn to a method of stimulating the immune response in a mammal comprising administering any one of SEQ ID NOs: 1-1477.

Applicants elect Groups 1479-2956 with traverse, Claim 7 drawn to an isolated polypeptide having at least 80% amino acid sequence identity to: (a) a polypeptide of SEQ ID NO: 1400; or

(b) a polypeptide encoded by the full length coding region of the nucleotide sequence of SEQ ID NO:1399. Applicants further elect SEQ ID NO:1399 (nucleic acid) and 1400 (polypeptide) as species for further prosecution. Applicants further request that Groups 2957-4434 (Claims 8 and 9) be examined together with Claim 7. Applicants traverse the restriction requirement because Claims 7, 8, and 9 can be easily searched together.


Applicants have canceled Claims 1-6 and 10-26, which are directed to non-elected subject matter. Claim 7 have been amended to delete the non-elected SEQ ID NOs. The amendments are fully supported by the specification and claims originally filed and do not introduce any new matter. Applicants reserve the right to pursue the canceled subject matters in a continuation, continuation-in-part, or a divisional application. Claims 7-9 are pending after the amendment. Applicants respectfully request that the Examiner consider the amendment.

### **CONCLUSION**

In conclusion, the present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned attorney at the telephone number shown below. Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. 07-1700 (referencing Attorney's Docket No. 123851-181686 R1 (formerly 39766-0275 R1)).

Respectfully submitted,

Dated: March 27, 2008

By:   
Panpan Gao (Reg. No. 43,626)

**GOODWIN PROCTER LLP**  
135 Commonwealth Drive  
Menlo Park, California 94025  
Telephone: (650) 752-3100  
Facsimile: (650) 853-1038  
LIBC/3251144.1